倍他赛未被批准用于AFIB/AFL适应症,因此不应替代倍他赛AF,因为只有倍他赛AF与患者包装插页一起分发,适用于AFIB/AFL患者。 spegra可以空腹吃吗 Spegra是一种复方制剂,用于治疗艾滋病(HIV)感染者,效果显著。最近很多患者都在问,空腹能吃spegra吗? 斯皮克拉可以和食物一起服用,也可以不吃。但是,有必要定期服用,以...
What's the difference between Sotalol and Sotalol AF? Sotalol AF is specifically used for maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (AFIB/AFL)] in patients with symptomatic AFIB/AFL who are currently in sinus rhythm. Plain Sotalol is ...
Inpharma Weekly -doi:10.2165/00128413-200012460-00034NoneSpringer International PublishingInpharma WeeklyNA;. (2000) New criteria needed to reduce risk of multiple pregnancies?. Inpharma Weekly &NA; , 16 /
CiNii Articles - PJ-426 D,I-Sotalol Reverses Atrial Electrical Remodeling and Prevents Atrial Fibrillation Promotion without Affecting Down-regulated L-type Ca2+ Channel mRNA Expression(PJ072,Atrial/Supraventricular Arrhythmia (Clinical/Treatment) 2 (A),Poster Session (Japanese),The 73rd Annual Scienti...
Sotalol: Torsade de pointes: clinical study [Citation only]
Effectiveness of sotalol for atrial flutter in children after surgery for congenital heart disease. Am J Cardiol 1997;79:92-4.Beaufort-Krol, G.C. and M.T. Bink-Boelkens, Effectiveness of sotalol for atrial flutter in children after surgery for congenital heart disease. Am. J. Cardiol ., ...
Amiodarone, sotalol, propafenone improve QOL in AFNo Abstract available for this article.doi:10.1007/BF03279432NA;Springer International PublishingPharmacoeconomics & Outcomes News
PROGNOSTIC IMPACT OF AMIODARONE COMPARED TO D, L-SOTALOL IN PATIENTS WITH IMPLANTABLE CARDIOVERTER DEFIBRILLATORKAZUTAKA AONUMA
Our study sought to understand the use of sotalol in AF patients and monitoring compliance across the USA and in the EU, with regards to the recent ESC guideline change. METHOD. An online physician survey of cardiologists, cardiac electrophysiologists (EPs) and interventional EPs (N = 569) ...
Sotalol or amiodarone + metoprolol prevent AF after cardiac surgeryInpharma Weekly -doi:10.2165/00128413-200414350-00032NoneSpringer International Publishinginpharma weekly